Endotronix announces development agreement for a new expanded U.S. headquarters in Naperville
Endotronix, Inc., a digital health and medical technology company dedicated to advancing the treatment of heart failure (HF), today announced plans to relocate and expand their headquarters in Naperville, Illinois to support the full U.S. commercial launch of its Cordella™ Heart Failure System and Pulmonary Artery (PA) Sensor, pending pre-market approval (PMA) of the sensor by the U.S. Food & Drug Administration (FDA). The new building will significantly increase Endotronix’s manufacturing and operating capacity, allowing for a 30% workforce expansion as well as continued growth opportunities in the years to come. In addition to the U.S. office, Endotronix will maintain their European office in Ireland.
“This is an exciting time for Endotronix. As we approach full enrollment in our PROACTIVE-HF clinical trial, we are looking ahead toward scaling our manufacturing and operations in anticipation of commercialization of our proactive digital heart failure system,” stated Harry Rowland, CEO of Endotronix. “Naperville offers an ideal location to plant our roots, offering a skilled workforce, affordable quality of life for our employees, desirable proximity to Chicago, and strong sense of community.”
Headquartered in the Chicago-land area since 2013, Endotronix recently signed a lease for an 80,000+ square feet facility that will more than double their current footprint. The new facility is located in the HUB 1415 building (1415 Diehl Road, Naperville, IL) and is currently undergoing custom enhancements to include a state-of-the-art cleanroom, manufacturing, quality, and administrative space. The first phase of construction is scheduled to be completed in early 2023 with hybrid workspace specifically designed to accommodate a flexible workforce. The company is represented by Newmark.
“It’s a pleasure to welcome Endotronix to Naperville,” said Steve Chirico, Mayor of Naperville. “As a fiscally-sound, business-friendly community that provides an unparalleled quality of life to its residents, we are a premier destination for growing companies like Endotronix. We look forward to being the home of their expanded commercial manufacturing and operations.”
The safety and efficacy of the company’s novel Cordella PA Sensor is currently being studied in a global investigational device exemption (IDE) clinical trial called PROACTIVE-HF that is on track to complete enrollment in the coming months. In addition, the company recently announced positive clinical data for the Cordella Sensor from the European SIRONA 2 clinical trial that was presented at the European Society of Cardiology’s Heart Failure Association (HFA) in May.
